Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information: www.uni-bioscience.com
About Sinopharm Weiqida Pharmaceutical Company Limited
Sinopharm Weiqida Pharmaceutical
Company Limited is wholly owned by the Shanghai Shyndec Pharmaceutical Company
Limited, and is located in Datong City, Shanxi Province; Sinopharm Weiqida is
an important API manufacturing plant base to the China National Pharmaceutical
Group Company Limited (Sinopharm). Sinopharm Weiqida has the leading
manufacturing and great capability production plant for API requiring
fermentation, and owns an integrated industry value chain for cephalosporin and
penicillin from API to formulation. As a famous leading company manufacturing and
exporting API, over 50% of Sinopharm Weiqida's product sales occurs in
international foreign market. The collaboration on Acarbose API involves
fermentation production, highly requiring fermentation equipment, production
capability and environment protection measures, which are advantages of Sinopharm
Weiqida . Please visit the official website of Shinopharm Weiqida
Pharmaceutical Company for more information:
About Suzhou Yingli Medical Technology Company Limited
Suzhou Yingli Medical Technology Company Limited is located in the Suzhou National University Science and Technology Park of Nanotechnology of Suzhou Industrial Park. Suzhou Yingli is an innovative company integrated with research and development, manufacturing, marketing and sales, and focuses on high-end pharmaceutical research and development for pharmaceutical intermediates, active ingredients and formulation technology. Since Suzhou Yingli was founded, Suzhou Yingli has developed several challenging high-end active ingredient development technologies for active ingredient projects requiring fermentation and synthesis.
About Boshutai® (Acarbose tablet)
Boshutai is the trade name of the acarbose tablets developed by Uni-Bio Science Group, which comes in two major dosage strengths, 50mg/tablet and 100mg/tablet.
Acarbose is clinically indicated for impaired glucose tolerance and diabetes type 2 patients to decrease post-prandial glucose level, listed as a first line therapeutic drug in the China Diabetes Prevention and Therapy Guide 2017, and listed as one of drugs in the National Essential Medicine List and National Basic Medical Insurance. Acarbose inhibits alpha glucosidase in the intestine to decrease glucose absorption, which is particularly suitable for Asian patients whom have high carbohydrate diets. According to International Diabetes Federation data, Diabetes population in China reached 114 million. The China diabetes drug market is expected to continue to grow quickly in the coming ten years due to drivers such as aging population, increasing diagnosis and treatment rate, and growing importance of chronic disease drug by the medical insurance policy in China. Acarbose already has the largest market share among oral hypoglycemic agents in China; according to the Chinese public healthcare institute sales data, Acarbose reached RMB 8.4 billion in sales in 2018, growing at double-digit CAGR in the past five years. In addition, Acarbose was listed in the 2nd round of China National Drug Centralized Procurement Scheme in the end in 2019, indicating high clinical value and large market size of Acarbose.